This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More
by Ahan Chakraborty
Let's look at five big biotech, pharma companies, PFE, MRK, VRTX, EXEL and INCY, slated to release quarterly results on Aug 1.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) second-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 87.50% and 36.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
New Strong Sell Stocks for June 16th
by Zacks Equity Research
ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
Incyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte
by Zacks Equity Research
Fomento Economico Mexicano, NextEra Energy, Charter Communications, General Electric and Incyte are included in this Analyst Blog.
Top Analyst Reports for Fomento Economico Mexicano, NextEra Energy & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Charter Communications, Inc. (CHTR).
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
by Zacks Equity Research
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
by Ekta Bagri
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Molina Healthcare (MOH) in Q1 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 results are likely to have benefited from the strong performance of its Medicaid and Medicare businesses, partly offset by rising operating costs.
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
by Zacks Equity Research
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
by Zacks Equity Research
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
by Zacks Equity Research
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
by Zacks Equity Research
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
by Zacks Equity Research
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
Company News for Mar 27, 2023
by Zacks Equity Research
Companies in The News Are: SQ,INCY,JPM,WFC